المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline Dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

المصدر: PLoS ONE, Vol 19, Iss 2, p e0299197 (2024)

مصطلحات موضوعية: Medicine, Science

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1932-6203

URL الوصول: https://doaj.org/article/8f9063cdddcc407b8037ccf8dcd06051

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Additional_information_on_methods_/25277619

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s003
https://figshare.com/articles/journal_contribution/Additional_information_on_methods_/25277619

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/CONSORT_checklist_/25277616

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s002
https://figshare.com/articles/journal_contribution/CONSORT_checklist_/25277616

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Study_protocol_/25277613

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s001
https://figshare.com/articles/journal_contribution/Study_protocol_/25277613

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Model_of_follow-up_telephone_interviews_/25277622

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s004
https://figshare.com/articles/journal_contribution/Model_of_follow-up_telephone_interviews_/25277622

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Adverse_Events_at_day_28_/25277637

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s008
https://figshare.com/articles/journal_contribution/Adverse_Events_at_day_28_/25277637

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Viral_load_measurements_with_available_results_in_each_group_/25277628

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s005
https://figshare.com/articles/journal_contribution/Viral_load_measurements_with_available_results_in_each_group_/25277628

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Additional_data_on_baseline_characteristics_/25277631

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s006
https://figshare.com/articles/journal_contribution/Additional_data_on_baseline_characteristics_/25277631

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Symptoms-free_days_up_to_day_10_/25277643

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s010
https://figshare.com/articles/journal_contribution/Symptoms-free_days_up_to_day_10_/25277643

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Sensitivity_analysis_for_the_primary_outcome_/25277646

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s011
https://figshare.com/articles/journal_contribution/Sensitivity_analysis_for_the_primary_outcome_/25277646

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Post-hoc_analysis_/25277649

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s012
https://figshare.com/articles/journal_contribution/Post-hoc_analysis_/25277649

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/dataset/Adverse_events_sup_a_sup_/25277703

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.t003
https://figshare.com/articles/dataset/Adverse_events_sup_a_sup_/25277703

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/figure/Respiratory_symptoms-free_days_up_to_day_10_/25277652

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s013
https://figshare.com/articles/figure/Respiratory_symptoms-free_days_up_to_day_10_/25277652

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/figure/Dyspnea-free_days_up_to_day_10_/25277658

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s015
https://figshare.com/articles/figure/Dyspnea-free_days_up_to_day_10_/25277658

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/dataset/S5_Table_-/25277640

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s009
https://figshare.com/articles/dataset/S5_Table_-/25277640

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/figure/Cough-free_days_up_to_day_10_/25277655

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s014
https://figshare.com/articles/figure/Cough-free_days_up_to_day_10_/25277655

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/figure/Gastrointestinal_symptoms-free_days_up_to_day_10_/25277667

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s017
https://figshare.com/articles/figure/Gastrointestinal_symptoms-free_days_up_to_day_10_/25277667

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/figure/Rhinorrhea-free_days_up_to_day_10_/25277661

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s016
https://figshare.com/articles/figure/Rhinorrhea-free_days_up_to_day_10_/25277661

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/dataset/Baseline_characteristics_of_the_patients_sup_a_sup_/25277697

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.t001
https://figshare.com/articles/dataset/Baseline_characteristics_of_the_patients_sup_a_sup_/25277697

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/figure/Nausea-free_days_up_to_day_10_/25277670

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s018
https://figshare.com/articles/figure/Nausea-free_days_up_to_day_10_/25277670